Allogene Therapeutics Ownership | Who Owns Allogene Therapeutics?

Overview Forecast RevenueFinancials Chart Transcripts

Allogene Therapeutics Ownership Summary

Allogene Therapeutics is owned by 88.67% institutional investors, 18.07% insiders. Fmr is the largest institutional shareholder, holding 11.36% of ALLO shares. American Funds SMALLCAP World A is the top mutual fund, with 3.29% of its assets in Allogene Therapeutics shares.

ALLO Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Allogene Therapeutics	88.67%	18.07%	-6.74%
Sector	Healthcare Stocks	57.39%	9.93%	32.68%
Industry	Biotech Stocks	68.48%	9.65%	21.87%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Fmr	23.77M	11.36%	$50.63M
Pfizer	22.03M	10.53%	$46.93M
Blackrock	16.45M	9.72%	$38.32M
Tpg gp a	18.72M	8.95%	$39.87M
Blackrock funding, inc. /de	18.06M	8.63%	$38.47M
Lynx1 capital management lp	10.87M	5.20%	$23.16M
Vanguard group	8.00M	3.82%	$17.04M
State street	7.25M	3.47%	$15.44M
Capital world investors	6.90M	3.30%	$14.69M
Primecap management co/ca/	4.93M	2.36%	$10.50M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Lynx1 capital management lp	10.87M	8.68%	$23.16M
Foresite capital management vi	3.45M	3.27%	$7.34M
Vida ventures advisors	1.80M	2.62%	$3.83M
Wildcat capital management	2.92M	2.46%	$6.22M
Pfizer	22.03M	1.81%	$46.93M
Patient square capital lp	1.49M	1.19%	$3.17M
Dafna capital management	1.24M	0.67%	$2.64M
Tpg gp a	18.72M	0.64%	$39.87M
Frazier life sciences management	2.87M	0.31%	$6.68M
Vestal point capital, lp	1.50M	0.19%	$3.19M

Top Buyers

Holder	Shares	% Assets	Change
Pfizer	22.03M	1.81%	22.03M
Blackrock	16.45M	0.00%	6.79M
Lynx1 capital management lp	10.87M	8.68%	4.67M
Foresite capital management vi	3.45M	3.27%	3.45M
Patient square capital lp	1.49M	1.19%	1.49M

Top Sellers

Holder	Shares	% Assets	Change
Fmr	23.77M	0.00%	-6.25M
Boxer capital	-	-	-3.85M
Perceptive advisors	-	-	-2.73M
Exoduspoint capital management, lp	-	-	-1.63M
Gsa capital partners llp	-	-	-835.34K

New Positions

Holder	Shares	% Assets	Change	Value
Pfizer	22.03M	1.81%	22.03M	$46.93M
Foresite capital management vi	3.45M	3.27%	3.45M	$7.34M
Patient square capital lp	1.49M	1.19%	1.49M	$3.17M
Gilead sciences	1.16M	0.16%	1.16M	$2.46M
Jacobs levy equity management	878.96K	0.01%	878.96K	$2.05M

Sold Out

Holder	Change
Capital performance advisors llp	-41.00
Dunhill financial	-70.00
Private wealth management group	-140.00
Bell investment advisors	-161.00
Westend capital management	-175.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2024	165	5.10%	185,488,005	12.84%	88	1.44%	89	27.14%	40	-11.11%
Sep 30, 2024	156	-8.77%	164,386,704	-0.47%	78	0.82%	71	-24.47%	45	9.76%
Jun 30, 2024	171	7.55%	165,168,429	25.95%	97	1.62%	94	23.68%	41	-4.65%
Mar 31, 2024	159	-5.92%	131,135,320	7.91%	77	1.49%	76	-15.56%	43	-14.00%
Dec 31, 2023	169	11.92%	121,517,475	-5.63%	72	1.22%	90	9.76%	50	47.06%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
American Funds SMALLCAP World A	6.90M	3.29%	-
Fidelity Growth Compy Commingled Pl O	4.58M	2.19%	-
Vanguard Total Stock Mkt Idx Inv	4.28M	2.02%	-
Vanguard US Total Market Shares ETF	4.34M	2.00%	-
Fidelity Select Health Care	4.00M	1.88%	-350.00K
SPDR® S&P Biotech ETF	3.90M	1.84%	-23.78K
Fidelity Growth Compy Commingled Pl S	3.77M	1.73%	-934.42K
Fidelity Series Small Cap Opps	3.54M	1.69%	-141.30K
iShares Russell 2000 ETF	3.38M	1.56%	-29.32K
Vanguard Capital Opportunity Inv	2.97M	1.42%	-596.71K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Mar 14, 2025	Chang David D	President and CEO	Sell	$91.47K
Mar 14, 2025	Beneski Benjamin Machinas	SVP, Chief Technical Officer	Sell	$10.84K
Feb 18, 2025	MESSEMER DEBORAH M.	-	Sell	$32.35K
Feb 03, 2025	Douglas Earl Martin	SVP, General Counsel	Sell	$10.95K
Feb 03, 2025	Parker Geoffrey M.	CHIEF FINANCIAL OFFICER	Sell	$7.54K

Insider Transactions Trends

Date	Buy	Sell
2025 Q1	-	7
2024 Q4	-	2
2024 Q3	-	-
2024 Q2	1	2
2024 Q1	1	-

ALLO Ownership FAQ

Who Owns Allogene Therapeutics?

Allogene Therapeutics shareholders are primarily institutional investors at 88.67%, followed by 18.07% insiders and -6.74% retail investors. The average institutional ownership in Allogene Therapeutics's industry, Biotech Stocks , is 68.48%, which Allogene Therapeutics exceeds.

Who owns the most shares of Allogene Therapeutics?

Allogene Therapeutics’s largest shareholders are Fmr (23.77M shares, 11.36%), Pfizer (22.03M shares, 10.53%), and Blackrock (16.45M shares, 9.72%). Together, they hold 31.62% of Allogene Therapeutics’s total shares outstanding.

Does Blackrock own Allogene Therapeutics?

Yes, BlackRock owns 9.72% of Allogene Therapeutics, totaling 16.45M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 38.32M$. In the last quarter, BlackRock increased its holdings by 6.79M shares, a 70.37% change.

Who is Allogene Therapeutics’s biggest shareholder by percentage of total assets invested?

Lynx1 capital management lp is Allogene Therapeutics’s biggest shareholder by percentage of total assets invested, with 8.68% of its assets in 10.87M Allogene Therapeutics shares, valued at 23.16M$.

Who is the top mutual fund holder of Allogene Therapeutics shares?

American Funds SMALLCAP World A is the top mutual fund holder of Allogene Therapeutics shares, with 3.29% of its total shares outstanding invested in 6.9M Allogene Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools